Clinical outcomes in one of four cycles of frozen-thawed embryo transfer cycles were increased by administering GnRH-a during the luteal phase: retrospective analysis

Abstract

Abstract we have conducted a Retrospective Cohort study and analyzed 3515 cycles of receiving FET at the Reproductive Center of the Second Affiliated Hospital of Zhengzhou University from February 2018 to December 2021. The Patients were divided into GnRH-a (triptorelin + existing treatment) group and No GnRH-a (existing treatment without Triptorelin) group. There were 1033 and 2485 cases in the study group and control groups. Clinical pregnancy Rate and Live Birth Rate were compared between two groups. We have found higher clinical pregnancy rates (58.0% vs. 48.4%, P = 0.003) and Live Birth Rates (52.7% vs. 45.6%, P = 0.001) for HRT-FET cycles, and found no clinical significance for NC-FET(58.2% vs 52.9%, P = 0.364) and (54.4%vs 47.0%,P = 0.211), GnRH-a + HRT-FET(53.0% vs 53.0% P = 0.176) and(46.2%vs47.3%, P = 0.794), and Stimulation-FET (59.3%vs52.9%, P = 0.566) and (59.3%vs47.1%, P = 0.247) in terms of clinical pregnancy rates and live birth rates between two groups. There was 47% increment of clinical pregnancy rate in the GnRH-a group and there was 33% increment of live birth rate in the GnRH-a group. During the FET cycles, administering of Triptorelin 3–4 times in the existing luteal support can improve the clinical pregnancy rate and live birth rate. Administering Triptorelin during the Luteal phase can be a new option for luteal support.